The Vetr crowd downgraded their rating for Juno Therapeutics Inc (NASDAQ: JUNO) on Thursday, from 4.5 stars (Strong Buy), issued 30 days go, to 1.5 stars (Strong Sell). At the time of the downgrade, crowd sentiment for Juno was edging positive, with 66 percent of Vetr user ratings bullish.
Vetr's downgrade on the pharmaceutical company comes after a bit of a selloff following the release of its earnings report on March 1. Juno posted revenue well above estimates, $21.153 million compared to $14.57 million.
The stock fell by more than 12 percent in the first few hours of Thursday's market to a low of $22.20. Shares finished the day at $22.62.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $22.32, which is still below the average analyst target price of $37.67. Less than 2 percent of Vetr users are holding JUNO in their watch lists.
Latest Ratings for JUNO
|Feb 2017||Wells Fargo||Initiates Coverage On||Outperform|
|Feb 2017||Wedbush||Initiates Coverage On||Neutral|
|Dec 2016||Raymond James||Downgrades||Outperform||Market Perform|
View More Analyst Ratings for JUNO
View the Latest Analyst Ratings
See more from Benzinga
- Vetr Urges Buy On The Heels Of Palo Alto's Earnings Miss
- When Will We See Fully Autonomous Vehicles? This Famous Hedge Fund Manager Thinks It Will Take 20 Years
- Vetr Downgrades The High-Flying Kite
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.